Tablet 0.18,0.35 & 0.7 mg

Pharmacological class

Non-ergot dopamine agonist, Antidyskinetic (dopamine agonist)


Parkinson's disease, idiopathic.

Pregnancy Category

FDA Pregnancy Category C

Adequate and well-controlled studies have not been done in humans


Because of the potential for serious adverse reactions in the nursing infant, discontinuation of nursing or discontinuation of pramipexole is recommended.




Safety and efficacy have not been established.


Pramipexole clearance was approximately 30% lower in subjects older than 65 years of age as compared with younger subjects because of an age-related reduction in renal function; this resulted in an increase in elimination half-life from approximately 8.5 hours to 12 hours. There were no other apparent differences in efficacy and safety of pramipexole between older and younger patients.

Contraindication & Drug interaction


Risk-benefit should be considered when the following medical problem exists:

Fibrotic complications from ergot-derived dopaminergic agents, history of.

Hallucinations, Hypotension, Orthostatic hypotension, Renal function impairment, Retinal degeneration, or retinal problem, Sensitivity to pramipexole.


Drug interactions

Combinations containing any of the following medications, depending on the amount present, may also interact with this medication.

Carbidopa and levodopa combination, Levodopa, Cimetidine, Dopamine antagonists , including:

Haloperidol , Metoclopramide ,Phenothiazines Thioxanthenes , Medications excreted by renal secretion, including: Diltiazem ,Quinidine ,Quinine, Ranitidine ,Triamterene &Verapamil .

Usual Adult Dose

Parkinson's disease, idiopathic-

In patients with normal renal function:Oral, initially 0.375 mg a day, administered in three divided doses. Dosages should be increased gradually at intervals of 5 to 7 days

Usual Pediatric Dose

Safety and efficacy have not been established

Side Effects

Those indicating need for medical attention:

Incidence more frequent

Asthenia, drowsiness, confusion, drowsiness; dyskinesia, hallucinations, insomnia, nausea, orthostatic hypotension.

Incidence less frequent

Akathisia, amnesia, confusion, diplopia or other eye or vision changes, dysphagia, edema, falling asleep without warning;  fever, frequent urination, muscle or joint pain, myasthenia, paranoid reaction, pneumonia, Abnormal thinking,chest pain ,delusions ,dizziness, peripheral edema, urinary incontinence ,urinary tract.

 Those indicating need for medical attention only if they continue or are bothersome

Incidence more frequent

Constipation; Dryness of mouth.

Incidence less frequent

Abnormal dreams, Anorexia ,Decreased libido or impotence ,increased sweating ,malaise ,rhinitis  skin problems, such as rash, weight loss


Store below 30oC.Keep the medicine in the box.Protect from light & moisture.


Boxes of 100  Scored Tablet 0.18, 0.35 & 0.7 mg






Address: 10th Km Karaj Road (Jadeh makhsoos),Tehran,Iran
Tel: (+98 ) 21 44504121-3
Email: info@loghman-med.com
© 2014 LOGHMAN Pharmaceutical & Hygienic Co.